BioCentury | Aug 29, 2019
Preclinical News

Aug. 29 Preclinical Quick Takes: New targets for leukemia from Calico and stroke from Gero; predictors of checkpoint inhibitor response and more

...Targets: CDK4 - Cyclin dependent kinase 4; CDK6 - Cyclin dependent kinase 6; DCAF15 - DDB1...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...For CRBN-mediated degraders, resistance emerges after loss of function of the substrate receptor CRBN, adaptor DDB1...
...cells. CRBN - Cereblon; CSN1; CUL2 - Cullin 2; CUL4A - Cullin 4A; DDB1 - Damage specific DNA binding protein 1...
BioCentury | Aug 4, 2016
Targets & Mechanisms

Cereblon ambition

...solved the crystal structure of GSTP1 complexed with CC-885 and cereblon, which was anchored to DDB1...
...IKAROS family zinc finger 3 Cereblon (CRBN) CSNK1A (CKI-α) - Casein kinase 1 α DDB1...
BioCentury | Apr 1, 2010
Targets & Mechanisms

Unlocking thalidomide

...a component in an E3 ubiquitin ligase complex. CRBN assembles with damage-specific DNA-binding protein 1 (DDB1...
BioCentury | Mar 25, 2002
Company News

DyoDelta Biosciences Ltd., University of Patras deal

DyoDelta received an exclusive license to the university’s DDB-202 myelin basic protein (MBP) epitope analog to treat multiple sclerosis (MS). The company said MBP is an autoantigen involved in MS. DyoDelta Biosciences Ltd. , London, U.K....
BioCentury | May 15, 1995
Company News

Pharma Mar S.A. deal

The Pasteur Institute (Paris) agreed to evaluate Pharma Mar's Dehydrodidemnin B (DDB) to modulate the immune system to fight HIV infection. The in vitro studies will evaluate the drug's effect on modulation of peripheral lymphocytes,...
Items per page:
1 - 6 of 6